Clinical Trials Using Defactinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Defactinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1205 locations

  • A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer

    This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Pembrolizumab with or without Defactinib before and after Surgery for the Treatment of Resectable Stage I-IIB Pancreatic Ductal Adenocarcinoma

    This phase II trial studies how well pembrolizumab with or without defactinib works before and after surgery for the treatment of stage I-IIB pancreatic ductal adenocarcinoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Defactinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with pembrolizumab, with and without defactinib.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland